| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_563c667842ce95888b891b6c7b99dca6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6043 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2018-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02c1cd33b4ee6659eef404b4b472b135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_704ad51afe41cc61cdd8f179e90a8370
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44f9f09e37ce47ac8916c97f4970e950
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_321fdea5e16c0ac0163605b58fd580c0 |
| publicationDate |
2020-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112020013033-A2 |
| titleOfInvention |
pharmaceutical composition, use of pharmaceutical composition, and method for treating an inflammatory disease. |
| abstract |
the invention relates to a pharmaceutical composition comprising the peptide apl-type identified as seq id no. 1, the sodium acetate buffer at pH 3.9 - 4.7; and at least one stabilizing sugar selected from sucrose or trehalose. this pharmaceutical composition is useful for the treatment of inflammatory diseases related to an increase in neutrophils or protein citrullination. these inflammatory diseases include rheumatoid arthritis (air), juvenile idiopathic arthritis (aij), ankylosing spondylitis (ea), alzheimer's disease and hepatic or pulmonary fibrosis. the invention also describes a method for the treatment of these diseases, by administering a therapeutically effective dose of the pharmaceutical composition of the peptide of the apl type identified as seq id no. 1. |
| priorityDate |
2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |